Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry

There is little data describing trends in the use of hydroxychloroquine for COVID-19 following publication of randomized trials that failed to demonstrate a benefit of this therapy. We identified 13,957 patients admitted for active COVID-19 at 85 U.S. hospitals participating in a national registry b...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2021-07, Vol.11 (1), p.15097-15097, Article 15097
Main Authors: Bradley, Steven M., Emmons-Bell, Sophia, Mutharasan, R. Kannan, Rodriguez, Fatima, Gupta, Divya, Roth, Gregory, Gluckman, Ty J., Shah, Rashmee U., Wang, Tracy Y., Khera, Rohan, Peterson, Pamela N., Das, Sandeep
Format: Article
Language:English
Subjects:
692/699/255/2514
704/844/1759
Aged
Antirheumatic Agents - therapeutic use
Cardiovascular Diseases - complications
Cardiovascular Diseases - drug therapy
Clinical trials
Coronaviruses
COVID-19
COVID-19 - complications
COVID-19 - drug therapy
COVID-19 - mortality
Cross-Sectional Studies
Female
Hospitalization
Humanities and Social Sciences
Humans
Hydroxychloroquine
Hydroxychloroquine - therapeutic use
Male
Middle Aged
multidisciplinary
Patients
Registries
Science
Science (multidisciplinary)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is little data describing trends in the use of hydroxychloroquine for COVID-19 following publication of randomized trials that failed to demonstrate a benefit of this therapy. We identified 13,957 patients admitted for active COVID-19 at 85 U.S. hospitals participating in a national registry between March 1 and August 31, 2020. The overall proportion of patients receiving hydroxychloroquine peaked at 55.2% in March and April and decreased to 4.8% in May and June and 0.8% in July and August. At the hospital-level, median use was 59.4% in March and April (IQR 48.5–71.5%, range 0–100%) and decreased to 0.3% (IQR 0–5.4%, range 0–100%) by May and June and 0% (IQR 0–1.3%, range 0–36.4%) by July and August. The rate and hospital-level uniformity in deimplementation of this ineffective therapy for COVID-19 reflects a rapid response to evolving clinical information and further study may offer strategies to inform deimplementation of ineffective clinical care.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-94203-7